Pharmaceutical composition suitable for primary treatment of extra-short-range treatment of smear-positive pulmonary tuberculosis
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A composition, tuberculosis technology, applied in the field of biomedicine, can solve the problem of not finding a drug composition, etc., and achieve the effect of shortening the treatment time, low recurrence rate, and low adverse reaction rate
Inactive Publication Date: 2021-02-02
BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
The main reason is that no suitable ph
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0030] Embodiment 1, be applicable to the composition of the pharmaceutical composition that treats newly diagnosed smear-positive pulmonary tuberculosis by 4.5 months chemotherapy regimen
[0031] The pharmaceutical composition provided by the present invention that is applicable to the treatment of newly diagnosed smear-positive pulmonary tuberculosis by 4.5 months chemotherapy regimen consists of levofloxacin, isoniazid, rifampicin, pyrazinamide and ethambutol, according to the unit dose (single day) Dosage) for packaging, specifically as follows (1) or (2):
[0032] (1) The pharmaceutical composition of the unit dose (single daily dose) contains 1 part of levofloxacin with a specification of 600 mg, 1 part of isoniazid with a specification of 300 mg, 1 part of rifampicin with a specification of 450 mg, and 3 parts of pyridoxine with a specification of 500 mg. Azinamide and 1 serving of ethambutol in a strength of 750 mg. It is suitable for newly diagnosed smear-positive p...
Embodiment 2
[0034] The specific application of pharmaceutical composition in embodiment 2, embodiment 1
[0035] 1. Subject population
[0036] 1. Conditions for using this program
[0037] (1) Sign the informed consent;
[0038] (2) Age 18-65;
[0039] (3) The sputum smear is positive twice or the culture is positive, and the chest X-ray shows that there are active tuberculosis lesions in the lungs;
[0040] (4) Never received anti-tuberculosis treatment or anti-tuberculosis treatment for less than 1 month;
[0041] (5) Relevant laboratory examinations shall be carried out before enrollment. Among them, ALT and total bilirubin were less than 2 times the upper limit of normal value. Creatinine clearance greater than 30ml / s / min. HB is greater than 7.0 g / dL. Platelets greater than 50×10 9 / L;
[0042] (6) Women of childbearing age have a negative urine pregnancy test and promise to take contraceptive measures during the course.
[0043] 2. Exclusions
[0044] (1) Combined with se...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses a pharmaceutical composition suitable for primary treatment of extra-short-range treatment of smear-positive pulmonary tuberculosis. The invention provides the pharmaceutical composition for treating primary treatment of smeared-positive pulmonary tuberculosis. The pharmaceutical composition is composed of levofloxacin, isoniazid, rifampicin, pyrazinamide and ethambutol. The pharmaceutical composition provided by the invention can be used for completing the primary treatment of the smeared-positive pulmonary tuberculosis through chemotherapy for four and a half months with a shorter range and higher efficiency, and compared with a standard six-month chemotherapy regimen, the pharmaceutical composition has the characteristic of high focus absorptivity, under the condition of ensuring a higher sputum culture negative conversion rate, a lower adverse reaction rate, a higher cure rate and a lower recurrence rate. According to the present invention, the treatment time of the primary treatment of the smeared-positive pulmonary tuberculosis can be shortened, and the pharmaceutical composition has important significance for reducing the prevalence and propagation oftuberculosis.
Description
technical field [0001] The invention relates to the field of biomedicine, in particular to a pharmaceutical composition suitable for ultra-short-course treatment of primary smear-positive pulmonary tuberculosis. Background technique [0002] Tuberculosis remains the most serious public health problem threatening people's health worldwide. According to the global report on tuberculosis released by the World Health Organization (WHO) in 2019, there were about 10 million new cases of tuberculosis in the world in 2018, with an incidence rate of 1.30 / 100,000. In 2018, there were 1.451 million deaths from tuberculosis. The number of tuberculosis cases in China is 866,000, accounting for 9% of the world, ranking second. Currently, the course of chemotherapy for newly diagnosed sensitive pulmonary tuberculosis is 6 to 9 months. Studies have shown that the longer the course of tuberculosis treatment, the higher the rate of irregular medication. In addition to reducing the cure ra...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more